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Summary: We have evaluated a recently introduced colour test kit for the determination of serum angioten-
sin I-converting enzyme catalytic activity. p-Hydroxyhippuric acid, liberated from p-hydroxyhippuryl-L-his-
tidyl-L-leucine by angiotensin I-converting enzyme, is cpnverted into a quinoneimine dye with an absorption
maximum at 505 nm. The procedure shows excellent linearity over the whole ränge of catalytic activities
found in serum. Intra- and inter-assay coefficients of Variation are 2—5 and 7—10% respectively. Correlation
with a modified Cushman-Cheung ((1971) Biochem. Pharmacol. 20, 1637—1648) method currently used in
our laboratory is good, with r = 0.985 and a regression equation of y (colour kit) = 0.423 (Cushman-
Cheung) + 0.765. Haemoglobin, lipids, bilirubin and prednisone do not interfere but uric acid in concentra-
tions higher than 600 / does. No extraction step is required. The assay is very rapid, and more than
twenty samples can be determined in an hour.
Bewertende Prüfung eines Testbestecks zur schnellen und einfachen kolorimetrischen Bestimmung
von Angiotensin I-Converting Enzyme im Serum
Zusammenfassung: Wir prüften einen kürzlich eingeführten Farbtest zur Bestimmung der katalytischen Kon-
zentration von Angiotensin I-Converting Enzyme im Serum. p-Hydroxyhippursäure wird durch das Enzyme
aus p-Hydrpxyhipptiryl-L-histidyl-L-leucin freigesetzt und zu einem Chinoniminfarbstoff mit einem Absorp-
tionsmaximum bei 505 nm umgesetzt. Das Verfahren zeigt über den gesamten im Serum vorkommenden
Bereich katalytischer Konzentration ausgezeichnete Linearität. Die Variationskoeffizienten betrugen 2—5%
in der Serie und 7—10% von Tag zu Tag. Die Korrelation mit einer in unserem Laboratorium laufend ge-
brauchten modifizierten Methode nach Cushman & Cheung ((1971) Biochem. Pharmakol. 20, 1637—1648)
ist mit r = 0,985 und einer Regressipnsgleichüng von y (Farbtest) = 0,423 (Cushman-Cheung-Methode) +
0,765 gut. Hämoglobin, Lipide, Bilirubin und Prednison stören die Methode nicht, wohl aber Harnsäure in
Konzentrationen >600 / . Ein Extraktionsschritt ist nicht erforderlich. Die Methode ist sehr schnell,
mehr als 20 Proben können in einer Stunde bestimmt werden.
Introduction
Determination of the serum catalytic activity of
angiotensin I-converting enzyme (EC 3.4.15.1) is in-
creasingly being used äs a vatuable tool in the diag-
nosis and inanagement of sarcoidosis (1—4) and cer-
tain other diseases such äs silicosis (5), asbestosis
(5), Gaucher's disease (6) and, possibly, malignant
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histiocytosis (7, 8). Serum angiotensin I-converting
enzyme is elevated in the active stages of these dis-
eases, äs it is in hyperthyroidism (9), in chronic liver
disease (10), and in diabetes mellitus with severe re-
tinopathy (l 1). In contrast, serum angiotensin I-con-
verting enzyme is depressed in patients with malig-
nant lymphomas (12), leukaemia (12), multiple
myeloma (12) and lung cancer (13).
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Many methods for determining angiotensin I-con-
verting enzyme have been described in the literature,
most of them based on the enzymatic cleavage of the
tripeptide Substrates hippuryl-L-histidyl-L-leucine
or hippuryl-glycyl-glycine. Quantitation of one of
the cleavage products, hippuric acid or the dipeptide,
has been achieved in a wide variety of ways: spectro-
photometric (14,15), fluorimetric (16,17), radioiso-
topic (18), colorimetric (19-21), or by HPLC (21-
23). In most assays, a time-consuming extraction
procedure is required. Recently, a diagnostic kit has
been introduced by the Fujizoki Pharmaceutical Co,
Tokyo, Japan, based on the colorimetric assay re-
ported by Kasahara & Ashihara (19). In this meth-
od, p-hydroxyhippuric acid is cleaved by angioten-
sin I-converting enzyme from the Substrate p-hy-
droxyhippuryl-L-histidyl-L-leucine and converted
into p-hydroxybenzoic acid by the enzyme hippuri-
case. Reaction with sodium periodate and 4-ami-
noantipyrine then yields a quinoneimine dye with an
absorption maxitnum at 505 nm. No extraction Step
is necessary, and the absorbance can be read within
minutes of stopping the incubation.
We have evaluated the performance of this angio-
tensin I-converting enzyme colour kit and compared
it with the modified Cushman-Cheung method (15),
which has been used in this laboratory for the last
few years.
Materials and Methods
Test k i t , chemica l s
Angiotensin I-converting enzyme colour kits (Fujizoki Pharma-
ceutical Co, Tokyo, Japan) were a gif t from Gist-Brpcades Phar-
maca Nederland BV, Rijswijk, The Netherlands. One package
contained four reagents:
1) l vial with 24 ml of buffer solution (0.12 mol/1 boric acid, 0.7
mol/1 sodium Chloride, pH 8.3);
2) 2 vials of lyophilized Substrate, which, after reconstitution with
11 ml of buffer solution each, contained 10 mmol/1 p-hydroxyhip-
puryl-L-histidyl-L-leucine, 2.5 mmol/1 4-aminoantipyrine and 3
kU/1 hippuricase;
3) 2 vials of stopper solution (31 ml each) containing 3 mmol/1
disodium ethylenediaminetetraacetate and 2 g/l Triton X-100;
and
4) 2 vials of lyophilized developer, each containing 6.5 mmol/1
sodium periodate after reconstitution with 31 ml of stopper solu-
tion.
Hippuryl-L-histidyl-L-leucine was obtained frorn Sigma, St.
Louis, USA.
Procedures
In the procedure recommended by the manufacturer, 0.5 ml of
the Substrate solution is added to 0.1 ml of sample serum in a test
tube. The tube is mixed and incubated at 37 °C for 20 minutes.
Then l .5 ml of the stopper/developer solution is added, and after
mixing and incubating at 37 °C fof 3 minutes, the absorbance is
read at 505 nm against distilled water. Blanks are prepared by
adding the sample serum aftef the 20 minutes incubation Step.
We have modified this procedure in three ways:
1) By halving the amounts of serum and reagents used and ern-
ploying semimicrocuvettes, twice s many samples can be assayed
with one paclcage.
2) The method of preparing blanks by adding serum after the in-
eubation step is rather inconvenient. We prepared blanks by pi-
petting serum in all test tubes at the same time, and by adding 10
μΐ of a disodium ethylenediaminetetraacetate solution (104 mg in
10 ml of 0.15 mol/1 NaCl, brought to pH 8.3 with l mol/1 NaOH)
to the tubes for the blanks. For 17 samples, blanks were prepared
according to the manufacturer and by our own method. Blank
absorbance (mean ± SEM) was 0.061 ± 0.015 and 0.067 ± 0.022
respectively, while calculated angiotensin I-converting enzyme ca-
talytic activity (mean ± SD) was 32.1 ± 22.8 vs. 31.6 ± 22.4
μΓηοΙ/min · l of p-hydroxyhippuric acid liberated.
3) To allow for the processing of a larger number of samples in the
same batch, we lengthened the incubation time to 30 nxiii tes,
with the added ad van tage of a higher sample absorbance.
For the evaluation of the kit we thus used the following proce-
dure: serum (50 μΐ) was pipetted into the test tubes; to the tubes
for the blanks were added 10 μΐ of a disodium ethylenediaminete-
traacetate solution (final concentration iri the incubation mixture
l mmol/1). Substrate solution (250 μΐ) was added, and the tubes
were mixed and incubated at 37 °C for 30 minutes. After adding
750 μΐ of the stopper/developer solution, followed by mixing and
incubating for 3 minutes at 37 °C, the absorbance was read at 505
nm. Samples were measured in duplicate.
Calculation:
Angiotensin I-converting enzyme (p^hydroxyhippuric acid, μιτιοί/
min · l = U/l) =
Asampie - Ablank 1-05 j_ ' 6
12000 X 0.05 30 l *
Results
Linearity
Three sera were incubated for various time intervals
s indicated in figure 1. Formation of p-hydroxyhip-
puric acid was found to be linear up to 130 nmol,
corresponding to a conversion of 5.2% of the sub-
strate. With an incubation time of 30 min and a sam-
ple portion of 50 μΐ, the ssay w ld thus be linear
up to an angiotensin I-converting enzyme catalytic
activity of 85 U/l. This was borne out in an experi-
ment in which three sera with increasing angioten-
sin I-converting enzyme catalytic activity were assay-
ed undiluted and in various dilutions with 0.15 mol/1
NaCl (fig. 2). Linearity was excellent, even for the
serum with the highest catalytic activity (84.6 U/l,
the highest we have ever encoiirjtered).
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Fig. l. Formation of /?-hydroxyhippuric acid vs. incubation time
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Fig. 2. Linear relationship between measured angiotensin I-eon-
verting enzyme catalytic activity and serum dilution in
three different sera. Dilutiofi is expressed s fraetion of
0.15 mol/1 NaCl in mixtures of serum and 0.15 mol/I
NaCl.
Precision
Sera with l w, medium and high angiotensin I-con-
verting enzyme catalytic activity were used for deter-
mining both within-run and between-run variability.
Reproducibility was good, s can be seen in table 1.
Tab. l. Variability of thc angiotensin 1-converting enzyme colour
test kit.







































In a series of 80 duplicate measurements (mean an-
giotensin I-converting enzyme 29.7 U/l) the Stand-
ard deviation of the differences between duplicates
was 2.0 U/l. In our opinion it is thus not necessary to
measure samples in duplicate. We recommend that
sera are briefly centrifuged before use, s pipetting
of turbid sera is probably one of the main causes of
measurement errors.
Comparison with the modified Cushman-Cheung
method
Angiotensin I-converting enzyme was determined in
71 samples with the colour kit s well s by the modi-
fied Cushman-Cheung method. An excellent corre-
lation was found between the two methods, with r =
0.985 (fig. 3). The regression line, calculated by the
least-squares method, was: y(colour kit) = 0.423 χ
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Fig. 3. Comparison of thc colour test kit (ordinate) with the mod-
ified Cushman-Cheung method (abscissa).
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the estimate Sy.x = 2.35 and Standard deviation of
the slope Sbyt = 0.0065. The Deming regression line
(24) was nearly identical: y(colour kit) = 0.429x
(Cushman-Cheung) + 0.413. The normal r nge with
the colour kit is 7—20 μιηοΐ/min - l of p-hydroxy-
hippuric acid (15—45 μπιοΐ/min · l of hippuric acid
with the modified Cushman-Cheung method).
Interference
Haemolytic sera, lipaemic sera, and sera with a high
bilirubin content were investigated and found not to
interfere in the determination of angiotensin I-con-
verting enzyme: results fitted the regression line with
the Cushman-Cheung method, and straight lines
were obtained when the samples were assayed after
dilution with 0.15 mol/1 NaCl. Blank absorbances
were higher than with normal sera (0.1—0.3). Uric
acid does interfere; when the uric acid concentration
of three normal sera (<0.6 mmol/1) was increased by
0.6, 1.5, 3.0 and 6.0 mmol/1, the measured catalytic
activity decreased by 5,12,15 and 21% respectively,
compared with fhe non-enriched sera.
Addition of various amounts of prednisone, up to
1.4 mmol/1, did not change the measured angioten-
sin I-converting enzyme value of serum.
Measurement of unblocked and total angiotensin l-
converting enzyme catalytic activity after captopril
Angiotensin I-converting enzyme can be blocked by
the converting enzyme Inhibitor captopril (Capo-
ten®), a new antihypertensive drug. We have pre-
viously reported that the angiotejqsin I-converting
enzyme Inhibition can be rapidly feversed in vitro by
the addition of Nrethylmaleimide to the incubation
mixture for the Cushman-Cheung method (final con-
centration 0.1 mmol/1), th s allowing the measure-
ment of total, i.e. blocked and unblocked angioten-
sin I-converting enzyme catalytic activity (15). To
see whether the same holds for the colour kit, we
added captopril (5 μg) to 1.5 ml f four sera. Angio-
tensin I-converting enzyme catalytic activity was
then determined in this plasma, and also after the
addition of various amounts of N-ethylmaleimide to
the incubation mixture. Results are shown in figure
4. The addition of captopril reduced the measured
catalytic activity to 0.06 of the original catalytic ac-
tivity, while addition of N-ethylmaleimide in final
concentrations of 0.1, 0.25, 0.5,0.75 and 1.0 mmol/1
resulted in a restoration to 0.68, 0.88, 0.78,0.66 and
0.50 respectively of the original catalytic activity.
The decrease in reversal of Inhibition with higher
concentrations of N-ethylmaleimide, which contrasts
with the increase seen with the Cushman-Cheung
method, is probably ca sed by interference of N-
ethylmaleimide with hippuricase.
Colour stability
The angiotensin I-converting enzyme catalytic activ-
ity of seven sera was calculated from the absorbance
measured immediately after the 3-min incubation
step with the stopper/developer solution, and subse-
quently from the absorbance measured after various
times at room temperature or at 4 °C. Results, ex-
pressed s the fraction of the activity calculated from
the immediately measured absorbance, are shown in
table 2.
Tab. 2. Colour stability of the reaction mixture. Results are ex-
pressed s the fraction of the catalytic activity calculated
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Fig. 4. Influence of N-ethylmaleimide on measured angioten-
sin I-eonverting enzyme catalytic activity in serum con-
t ining captopril.
O measured by the modified Cushman-Cheung method
O measured by the Fujizoki method
Points are means of four experiiifents.
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Discussion
In contrast to the Cushman-Cheung method, the co-
lour kit shows excellent linearity over the whole
ränge of angiotensin I-converting enzyme catalytic
activities likely to be encountered in serum. This dif-
ference can, at least partly, be attributed to the lower
Vmax of the reaction of angiotensin I-converting en-
zyme with p-hydroxyhippuryl-L-histidyl-L-leucine
äs compared with hippuryl-L-histidyl-L-leucine
(19), resulting in a lower rate of hydrolysis with the
colour kit than with methods employing hippuryl-L-
histidyl-L-leucine. It is of interest to note the differ-
ence in Chloride dependency. With hippuryl-L-his-
tidyl-L-leucine, the optimal Chloride concentration
in the incubation mixture is 0.3 mol/1 (14), whereas
in the colour kit, using p-hydroxyhippuryl-L-histid-
yl-L-leucine äs a Substrate, the optimal concentra-
tion of Chloride is 0.58 mol/1 (25).
The lower rate of hydrolysis makes the colour kit less
sensitive than some other methods described in the
literature, but this is hardly a disadvantage, since the
sensitivity is adequate for measuring angiotensin I-
converting enzyme in serum. The sensitivity might
become a limiting factor only when precise measure-
ments are needed in fluids other than serum, with
much lower angiotensin I-converting enzyme cata-
lytic activity, or in sera containing converting en-
zyme inhibitors. In these cases, however, the sensi-
tivity of the colour kit can be enhanced by modifying
the procedure, e.g. by a longer incubation time or by
using a larger volume of the sample.
The precision of the assay is good. Both serum and
heparinized plasma can be used, äs in the Cushman-
Cheung method. Only uric acid in abnormally high
concentrations was found to interfere.
The method for measuring total angiotensin I-con-
verting enzyme catalytic activity in sera of patients
treated with captopril is not fully applicable when us-
ing the colour kit. Nearly 0.90 of the total activity is
measured, however, when N-ethylmaleimide is pres-
ent in the incubation mixture in a concentration of
0.25 mmol/1. This is adequate if one just wants to
check 'patient compliance'.
In conclusion, we find the colour kit to be a simple,
reliable and rapid method for determining serum an-
giotensin I-converting enzyme catalytic activity.
Twenty or more samples can be measured in an
hour. No extraction procedure is necessary, and only
a simple spectrophotometer is required.
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